Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Micrus Endovascular Corporation

Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Micrus Endovascular Corporation (NASDAQ: MEND - News) (referred to as "Micrus Endovascular" or the “Company”) by Johnson & Johnson (NYSE: JNJ - NEWS) (referred to as "Johnson") in a cash transaction with an estimated value of approximately $480 million.

Under the terms and conditions of the merger agreement, Micrus Endovascular stockholders will receive at closing $23.40 in cash for each Micrus Endovascular share they own.

Bull & Lifshitz, LLP's investigation is focused on whether the proposed deal provides adequate value to the Company’s shareholders.

If you are a holder of Micrus Endovascular stock and want to discuss your legal rights, you may e-mail or call Bull & Lifshitz, LLP who will, without obligation or cost to you, attempt to answer your questions.

If you are a shareholder of Micrus Endovascular and would like more information about our investigation, please contact Peter D. Bull, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail]. All e-mail correspondence should make reference to Micrus Endovascular.

Bull & Lifshitz, LLP is a New York City-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at www.nyclasslaw.com.

ATTORNEY ADVERTISING. © 2010 Bull & Lifshitz, LLP. The law firm responsible for this advertisement is Bull & Lifshitz, LLP, 18 East 41st Street, New York, New York 10017, [phone]. Prior results do not guarantee or predict a similar outcome with respect to any future matter.